Investors and Media
We are focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways and commercial opportunities.
Our team consists of industry veterans with a proven track record of improving the lives of patients with debilitating diseases.
Our lead candidate, LX-101, is a targeted therapy for oncology and autoimmune diseases, including thyroid eye disease (TED).
Partner with Us
We are always seeking novel compounds to add to our development portfolio.
October 31, 2023
Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against Pediatric Sarcomas
February 8, 2023
Lirum Therapeutics announces closing of $7 million private placement of common stock